KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Accured Expenses (2016 - 2025)

Nektar Therapeutics has reported Change in Accured Expenses over the past 16 years, most recently at -$2.7 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$2.7 million for Q4 2025, up 58.64% from a year ago — trailing twelve months through Dec 2025 was -$5.8 million (down 153.9% YoY), and the annual figure for FY2025 was -$5.8 million, down 153.9%.
  • Change in Accured Expenses for Q4 2025 was -$2.7 million at Nektar Therapeutics, up from -$7.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for NKTR hit a ceiling of $22.1 million in Q2 2021 and a floor of -$21.5 million in Q4 2022.
  • Median Change in Accured Expenses over the past 5 years was -$1.9 million (2022), compared with a mean of -$2.8 million.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 770.7% in 2023 and later soared 1489.56% in 2024.
  • Nektar Therapeutics' Change in Accured Expenses stood at -$18.5 million in 2021, then decreased by 16.58% to -$21.5 million in 2022, then soared by 54.77% to -$9.7 million in 2023, then soared by 32.45% to -$6.6 million in 2024, then soared by 58.64% to -$2.7 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$2.7 million (Q4 2025), -$7.0 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.